Biomerica (BMRA) Competitors $3.27 -0.13 (-3.82%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$3.36 +0.09 (+2.75%) As of 07/8/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. ESLA, BDRX, RANI, EYEN, MRNS, DYAI, KALA, ALLK, MAAQ, and ENLVShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Estrella Immunopharma (ESLA), Biodexa Pharmaceuticals (BDRX), Rani Therapeutics (RANI), Eyenovia (EYEN), Marinus Pharmaceuticals (MRNS), Dyadic International (DYAI), KALA BIO (KALA), Allakos (ALLK), Mana Capital Acquisition (MAAQ), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Its Competitors Estrella Immunopharma Biodexa Pharmaceuticals Rani Therapeutics Eyenovia Marinus Pharmaceuticals Dyadic International KALA BIO Allakos Mana Capital Acquisition Enlivex Therapeutics Estrella Immunopharma (NASDAQ:ESLA) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Is ESLA or BMRA more profitable? Estrella Immunopharma has a net margin of 0.00% compared to Biomerica's net margin of -85.42%. Biomerica's return on equity of -85.90% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -1,132.38% -273.91% Biomerica -85.42%-85.90%-61.06% Does the media refer more to ESLA or BMRA? In the previous week, Biomerica had 5 more articles in the media than Estrella Immunopharma. MarketBeat recorded 5 mentions for Biomerica and 0 mentions for Estrella Immunopharma. Biomerica's average media sentiment score of 0.65 beat Estrella Immunopharma's score of 0.00 indicating that Biomerica is being referred to more favorably in the news media. Company Overall Sentiment Estrella Immunopharma Neutral Biomerica Positive Do analysts prefer ESLA or BMRA? Estrella Immunopharma currently has a consensus target price of $16.00, indicating a potential upside of 1,736.13%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Estrella Immunopharma is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings & valuation, ESLA or BMRA? Biomerica has higher revenue and earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.35Biomerica$5.41M1.54-$5.98M-$2.32-1.41 Do insiders and institutionals believe in ESLA or BMRA? 0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 55.1% of Estrella Immunopharma shares are held by insiders. Comparatively, 15.0% of Biomerica shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, ESLA or BMRA? Estrella Immunopharma has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. SummaryBiomerica beats Estrella Immunopharma on 8 of the 15 factors compared between the two stocks. Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.66M$2.39B$5.47B$8.95BDividend YieldN/A1.80%5.25%4.04%P/E Ratio-1.418.9827.0020.11Price / Sales1.54729.49429.45119.84Price / CashN/A159.8036.8257.86Price / Book1.044.517.985.56Net Income-$5.98M$31.26M$3.16B$248.40M7 Day Performance1.24%3.57%2.38%4.67%1 Month Performance-4.39%1.28%2.17%6.64%1 Year Performance-4.54%1.08%33.80%21.31% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica0.3764 of 5 stars$3.27-3.8%N/A-7.4%$8.66M$5.41M-1.4160ESLAEstrella Immunopharma2.2166 of 5 stars$0.96+9.0%$16.00+1,566.7%-29.7%$31.86MN/A-3.69N/APositive NewsGap DownBDRXBiodexa PharmaceuticalsN/A$0.87-0.6%N/AN/A$31.79M$470K0.0020Upcoming EarningsRANIRani Therapeutics1.4906 of 5 stars$0.51-6.9%$7.33+1,327.0%-83.3%$31.73M$1.03M-0.52110News CoverageEYENEyenovia0.996 of 5 stars$10.38-4.6%$2.00-80.7%-77.3%$31.36M$60K-0.1840High Trading VolumeMRNSMarinus Pharmaceuticals2.3196 of 5 stars$0.55-0.2%$3.92+613.3%-54.2%$30.32M$30.99M-0.22110DYAIDyadic International1.9966 of 5 stars$0.99-0.9%$6.00+506.1%-33.4%$30.06M$3.49M-4.957Gap DownKALAKALA BIO3.4674 of 5 stars$4.76+3.0%$13.50+183.6%-24.2%$29.81M$3.89M-0.5830News CoverageALLKAllakos3.0215 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190MAAQMana Capital AcquisitionN/A$3.61+9.4%N/A-36.7%$29.33MN/A0.001High Trading VolumeENLVEnlivex Therapeutics3.1642 of 5 stars$1.12-6.7%$10.00+792.9%-11.9%$28.38MN/A-1.7070Positive News Related Companies and Tools Related Companies Estrella Immunopharma Alternatives Biodexa Pharmaceuticals Alternatives Rani Therapeutics Alternatives Eyenovia Alternatives Marinus Pharmaceuticals Alternatives Dyadic International Alternatives KALA BIO Alternatives Allakos Alternatives Mana Capital Acquisition Alternatives Enlivex Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMRA Stock Alerts